Tag: PROMISE II
Deep vein arterialisation: “A real advance” for treatment of ‘no-option’ CLTI
Daniel Clair (Vanderbilt University Medical Center, Nashville, USA) speaks to Vascular News at this year’s VEITHsymposium (14–18 November, New York, USA) on deep vein...
Results from PROMISE II pivotal trial suggest “transformational value” of deep...
Results from the PROMISE II pivotal trial investigating transcatheter arterialisation of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischaemia...
LimFlow raises US$40 million in Series D financing
LimFlow recently announced it has closed a US$40 million (€36 million) oversubscribed Series D financing round.
A press release reports that new investors Longitude...
PROMISE II US pivotal trial of device designed for “no-option” CLTI...
Enrolment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialisation system (LimFlow SA) designed to prevent amputations in...
LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology
LimFlow announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification (CTN) for the Japanese cohort of...
LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology
LimFlow SA announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification for the Japanese cohort of...
First CLTI patient enrolled in PROMISE II pivotal study of LimFlow...
LimFlow, a specialist in minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), has announced...
